| 1 |
28337527 | Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma. | 2017 Jun |
1 |
| 2 |
27843623 | Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib. | 2016 |
1 |
| 3 |
26259250 | Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1. | 2015 Sep 8 |
1 |
| 4 |
24337769 | A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer. | 2014 Apr |
1 |
| 5 |
24737778 | A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors. | 2014 Jul |
2 |
| 6 |
23022995 | c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. | 2013 Feb |
1 |
| 7 |
23413279 | The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors. | 2013 Jun |
1 |
| 8 |
23598276 | Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. | 2013 May 15 |
1 |
| 9 |
22027690 | Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown. | 2012 Jan |
1 |
| 10 |
21383285 | Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. | 2011 Apr 1 |
2 |
| 11 |
21454604 | Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. | 2011 Jun 10 |
4 |
| 12 |
21632449 | Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers. | 2011 |
2 |
| 13 |
20484018 | ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. | 2010 Jun |
5 |